Furthermore, dasatinib, a multikinase inhibitor used to treat some types of leukemias, efficiently blocks VAV1 activation and subsequent RHOA-G17V signaling [88], pointing out a new possible therapeutic approach for AITL patients. This evidence concerns the gene VAV1 and angioimmunoblastic T-cell lymphoma.